ERBB2 and breast carcinoma: MAL2 expression was only reduced by BET inhibition in cell lines representing HER2 + and TN breast cancer subtypes, but it was curiously increased after 24 h of treatment in the TN BT549, perhaps as an indirect effect of BET inhibition on downregulating MAL2 repressors.